- Home
- Equipment
- usa california
- t cell receptors
Refine by
T Cell Receptors Equipment Supplied In Usa California
6 equipment items found
by:Sorrento Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
Sorrento utilizes a proprietary knock-out knock-in (KOKI) technology to modify normal healthy donor derived T cells to genetically engineer them to express the dimeric antigen receptor into T-cell receptor (TCR) alpha chain constant region (TRAC). In this manner, TRAC is knocked out and ...
by:Ionpath, Inc. based inMenlo Park, CALIFORNIA (USA)
Background:Arginase-1 is expressed by liver cells, myeloid-derived suppressor cells (MDSCs), macrophages, and neutrophils. In mammals, there are three enzymes that metabolise arginine: two arginase isoforms (ARG1, ARG2) and inducible nitric oxide synthase (iNOS). Arginase-1 catalyzes the breakdown of L-arginine into L-ornithine and urea as the final step in the ...
Manufactured by:Ardigen based inKraków, POLAND
Accelerate discovery and improve safety of TCR therapies using Artificial Intelligence. Following the unique opportunity for curing patients provided by the development of cell therapies (e.g. TCR discovery), Ardigen has set on the path to advance the field with its Artificial Intelligence platform. Many challenges stand in the way of successful therapy discovery and development. Let us know how ...
Manufactured by:Adaptive Biotechnologies based inSeattle, WASHINGTON (USA)
We are currently leveraging our TCR discovery capabilities to enable commercialization of novel therapies by collaborators. In the future, we may explore expanding our end-to-end capabilities for the development of cellular therapies and vaccines. TruTCR is summarized in the figure ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
CAR T-cell therapy has recently emerged as a revolutionary and potentially curative therapy for patients with certain hematologic malignancies, including refractory cancers. In 2017, two CAR T-cell therapies were approved by the FDA for the treatment of relapsed / refractory B-cell precursor acute lymphoblastic leukemia (ALL) and relapsed / refractory diffuse large B-cell lymphoma (DLBCL). While ...
Manufactured by:Adicet Bio based inMenlo Park, CALIFORNIA (USA)
Gamma delta T cells represent a new generation of universal cell therapy. The current engineered autologous alpha beta T cell products have shown significant efficacy in hematological malignancies; however comparable efficacy in solid tumors is yet to be proven. The cell platform and novel targeting approaches Adicet is developing are aimed at harnessing the tumor specific immunity of gamma delta ...